Molecular biology

Areteia Therapeutics Announces Appointment of Daniel Becker, M.D., Ph.D. To Board of Directors

Retrieved on: 
Thursday, February 15, 2024

Areteia Therapeutics, Inc. (“Areteia”) today announced the appointment of Daniel Becker to the Areteia Board of Directors, effective immediately.

Key Points: 
  • Areteia Therapeutics, Inc. (“Areteia”) today announced the appointment of Daniel Becker to the Areteia Board of Directors, effective immediately.
  • Dr. Becker will serve as a member of the audit committee of the board.
  • View the full release here: https://www.businesswire.com/news/home/20240215803782/en/
    “I am excited that Dan has been appointed to our board,” said Jorge Bartolome, President and Chief Executive Officer of Areteia.
  • and Ph.D. (Cellular and Molecular Biology) degrees from the University of Michigan and received his B.S.

Reproductive Partners Medical Group, an Ivy Fertility Clinic, Expands With New Providers And New Location

Retrieved on: 
Wednesday, February 14, 2024

Dr. Chang and Dr. Brower are both double board certified reproductive endocrinologists and infertility specialists.

Key Points: 
  • Dr. Chang and Dr. Brower are both double board certified reproductive endocrinologists and infertility specialists.
  • “Reproductive Partners Medical Group has stayed at the forefront of our field by honoring our heritage of excellence while continually looking toward the future,” said Lab Medical Director Gayane Ambartsumyan, MD.
  • She received her medical degree from University of California, Davis, and completed her residency in Obstetrics, Gynecology, and Reproductive Medicine at Harvard Medical School.
  • “This is an exciting time to join Reproductive Partners Medical Group and Ivy Fertility,” said Dr. Brower.

New ex-vivo study on low and no calorie sweeteners finds positive impact or no impact on human gut microbiota

Retrieved on: 
Thursday, February 8, 2024

Tate & Lyle and Cryptobiotix's breakthrough ex-vivo* study shows that sucralose does not impact the gut microbiota, while other low and no calorie sweeteners have potentially beneficial health effects

Key Points: 
  • Tate & Lyle and Cryptobiotix's breakthrough ex-vivo* study shows that sucralose does not impact the gut microbiota, while other low and no calorie sweeteners have potentially beneficial health effects
    LONDON, Feb. 8, 2024 /PRNewswire/ - A new, first-of-its-kind study has identified unique and potentially beneficial interactions between certain low and no calorie sweeteners, including stevia, and the human gut microbiota.
  • The doses of low and no calorie sweeteners used were based on actual intakes, regulations and amounts that are generally included in foods and beverages during different timepoints.
  • Assessments of additional low and no calorie sweeteners, including allulose and erythritol, are being completed and details will be shared in due course.
  • The low and no calorie sweeteners studied for this paper included: Acesulfame potassium (aceK), maltitol, sorbitol, stevia, sucralose and tagatose.

Volta Labs Partners with OEM by QIAGEN to Unlock Potential of NGS Sample Prep

Retrieved on: 
Thursday, February 8, 2024

Volta Labs and OEM by QIAGEN will partner on the production of reagents and other elements necessary for the development of the Callisto sample preparation kits.

Key Points: 
  • Volta Labs and OEM by QIAGEN will partner on the production of reagents and other elements necessary for the development of the Callisto sample preparation kits.
  • "QIAGEN has paved the way for the acceleration of sample prep and has set the standard for many genomics workflows," said Udayan Umapathi, CEO at Volta Labs.
  • "At OEM by QIAGEN, we are committed to supporting companies like Volta Labs in their mission to revolutionize the field of molecular biology.
  • In supplying reagents for their innovative Callisto Sample Prep System, our partnership aims to elevate NGS technology, addressing the critical bottleneck in NGS sample & library preparation," said Salim Essakali, VP, Head of the OEM Business at QIAGEN.

Domain Therapeutics Further Strengthens Leadership Team With Appointment of Sean A. MacDonald as Chief Business Officer

Retrieved on: 
Thursday, February 8, 2024

Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the appointment of Sean A. MacDonald as its Chief Business Officer (CBO) and member of the executive management team.

Key Points: 
  • Domain Therapeutics (“Domain” or “the Company”), a clinical-stage global biopharmaceutical company developing innovative drug candidates in immuno-oncology targeting G Protein-Coupled Receptors (GPCRs), today announces the appointment of Sean A. MacDonald as its Chief Business Officer (CBO) and member of the executive management team.
  • Over the past year, Sean worked with Domain as an independent Senior Advisor, providing strategic input and support to the Company’s management team.
  • This included positions such as Chief Business Officer of iOnctura, Head of Business Development for Cosmo Pharmaceuticals, President and Chief Executive Officer of Corbin Therapeutics Inc, and Vice President of Corporate and Business development at Pharmascience Inc.
  • Dr. Tony Johnson, President and Chief Executive Officer of Domain Therapeutics, said: “This is an incredible time for Domain Therapeutics, and as the Company continues to grow, I am thrilled to officially welcome Sean to the team.

Discoverer of the Klotho Gene and Pioneer in Longevity and Disease Prevention Dr. Makoto Kuro-o Joins Scientific Advisory Board of ADvantage Therapeutics

Retrieved on: 
Monday, February 5, 2024

Kuro-o and Madden will speak at the invite-only Entrepreneurship, Longevity, and Biotech Conference in Boca Raton on February 9 and 10.

Key Points: 
  • Kuro-o and Madden will speak at the invite-only Entrepreneurship, Longevity, and Biotech Conference in Boca Raton on February 9 and 10.
  • The conference assembles biotech and longevity scientists and entrepreneurs to share research and exchange ideas for improving the biotech and longevity industries.
  • He discovered and named the klotho gene in 1997, and since then has written and published extensively on the topic.
  • His pioneering research has opened new and promising paths toward understanding longevity as well as preventing and treating disease.

Resalis Therapeutics Appoints Almut Nitsche as Chief Medical and Development Officer

Retrieved on: 
Thursday, February 1, 2024

Resalis Therapeutics today announced the appointment of Almut Nitsche, PhD, as its Chief Medical & Development Officer (CMDO).

Key Points: 
  • Resalis Therapeutics today announced the appointment of Almut Nitsche, PhD, as its Chief Medical & Development Officer (CMDO).
  • In her role at Resalis, she will spearhead the clinical development of RES-010, a non-coding RNA drug candidate designed to address obesity.
  • I look forward to joining the Resalis team as we advance into the Phase 1 trial and seek to establish initial clinical proof of concept for RES-010,” added Almut Nitsche, CMDO of Resalis Therapeutics.
  • Dr. Almut Nitsche is a seasoned expert in pharmaceutical research and development.

Enhanc3D Genomics appoints Dr Daniel Turner as Chief Scientific Officer

Retrieved on: 
Wednesday, January 31, 2024

Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Dr Daniel Turner as Chief Scientific Officer (CSO).

Key Points: 
  • Enhanc3D Genomics, a company developing disruptive technologies to unlock the 3D spatial genome for target and biomarker discovery, today announced the appointment of Dr Daniel Turner as Chief Scientific Officer (CSO).
  • Dan’s deep expertise in genomics technology development and commercialisation will be key to achieving the next phase of Enhanc3D Genomics’ growth.
  • Dr Hazel Jones, Chief Operating Officer and interim Chief Executive Officer, Enhanc3D Genomics, said: “Dan joins us at an exciting stage in the Company’s development as we begin to steer towards commercialisation.
  • I look forward to working alongside Dan as he joins the team.”
    Dr Dan Turner, Chief Scientific Officer, Enhanc3D Genomics, commented: “Enhanc3D Genomics has an exceptional reputation in the field of 3D genomics, and I’m delighted to take this opportunity to help drive the development of its technology further.

Checkerspot Announces Breakthrough with the Development of Human Milk Fat Analogue by Fermentation of Microalgae

Retrieved on: 
Tuesday, January 30, 2024

Checkerspot, a biotechnology company and Certified B Corporation™ that produces unique oils through the fermentation of microalgae, published in Frontiers in Nutrition a breakthrough in the development of a new source of human milk fat analogue known as OPO (Oleic-Palmitic-Oleic or sn-2 palmitate).

Key Points: 
  • Checkerspot, a biotechnology company and Certified B Corporation™ that produces unique oils through the fermentation of microalgae, published in Frontiers in Nutrition a breakthrough in the development of a new source of human milk fat analogue known as OPO (Oleic-Palmitic-Oleic or sn-2 palmitate).
  • Checkerspot is dedicated to advancing the science of viable alternatives by harnessing the potential of its microalgae-based molecular biology and fermentation capabilities.
  • Infant formulas currently available in the market often incorporate structured triglycerides through human milk fat substitutes produced enzymatically.
  • We obtained a unique human milk fat analog containing palmitic acid in sn-2 position in the range of 73% of total palmitic acid.

Beacon Biosignals welcomes David Matthews, PhD, as Chief Business Officer

Retrieved on: 
Thursday, February 1, 2024

BOSTON, Feb. 1, 2024 /PRNewswire/ -- Beacon Biosignals, a leading computational neurodiagnostics and EEG analytics company, has appointed David Matthews, PhD, as Chief Business Officer to oversee commercial and strategic activities.

Key Points: 
  • Beacon Biosignals partners with top biopharma companies to better understand brain health using clinical-grade EEG and AI-powered analysis.
  • The company's Dreem 3S wearable medical device enables validated sleep endpoints at-home and unlocks a scale of brain activity data never before available.
  • Dr. Matthews will draw on his deep expertise in healthcare strategy, commercial development, and computational neuroscience to create new partnerships, expand relationships, and drive continued innovation for Beacon Biosignals through the company's next phase of growth.
  • "We are thrilled to welcome David to our leadership team," said Jacob Donoghue, MD PhD, CEO of Beacon Biosignals.